Paxlovid Approved for COVID-19 Treatment in High-Risk Adults

Last week, the FDA approved the oral antiviral Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

Paxlovid is the 4^th drug—and first oral antiviral pill—approved by the FDA to treat COVID-19 in adults.

Paxlovid manufactured and packaged under the EUA and distributed by the HHS will continue to be available to ensure continued access for adults, as well as treatment of eligible children ages 12-18 who are not covered by the FDA approval.

Paxlovid is not authorized for use as a pre-exposure or post-exposure prophylaxis for prevention of COVID-19.